Automate Your Wheel Strategy on BSX
With Tiblio's Option Bot, you can configure your own wheel strategy including BSX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BSX
- Rev/Share 12.5086
- Book/Share 15.3216
- PB 6.4388
- Debt/Equity 0.5365
- CurrentRatio 1.3721
- ROIC 0.0701
- MktCap 144663412027.0
- FreeCF/Share 2.2394
- PFCF 43.6918
- PE 57.6922
- Debt/Assets 0.2894
- DivYield 0
- ROE 0.1149
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | BSX | Oppenheimer | Perform | Outperform | -- | $125 | Sept. 8, 2025 |
| Initiation | BSX | Leerink Partners | -- | Outperform | -- | $118 | June 16, 2025 |
| Upgrade | BSX | Needham | Hold | Buy | -- | $113 | April 16, 2025 |
| Upgrade | BSX | Deutsche Bank | Hold | Buy | -- | $108 | Jan. 10, 2025 |
| Downgrade | BSX | Needham | Buy | Hold | -- | -- | Oct. 18, 2024 |
News
Best Momentum Stocks to Buy for February 10th
BSX,
CFR,
ENVA
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
BSX, ENVA and CFR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 10, 2025.
Read More
New Strong Buy Stocks for February 10th
BSX,
ENVA,
NFG,
NLY,
PFIS
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
PFIS, BSX, ENVA, NFG and NLY have been added to the Zacks Rank #1 (Strong Buy) List on February 10, 2025.
Read More
About Boston Scientific Corporation (BSX)
- IPO Date 1992-05-19
- Website https://www.bostonscientific.com
- Industry Medical - Devices
- CEO Michael F. Mahoney
- Employees 53000
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.